首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 生物科技 > 再生醫學 > 幹細胞：全球的幹細胞移植・臍帶血銀行・藥劑開發市場
產業/市場分類
生物科技 (1574)
分子標靶治療學 (131)
生技設備 (354)
生物材料 (53)
生物標記 (155)
以基因為基之藥物開發 (202)
再生醫學 (119)
抗體和免疫 (189)
個人化醫學 (51)
基因治療學和RNAi (102)
市場調查報告書

幹細胞：全球的幹細胞移植・臍帶血銀行・藥劑開發市場

Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development

出版商 Kalorama Information
出版日期 2012年01月 商品編碼 227816
內容資訊 英文 160 Pages
價格
US $ 3995 PDF by E-mail (Single User License)
US $ 5995 PDF by E-mail (Departmental License)
US $ 7990 PDF by E-mail (Global Site License)


幹細胞：全球的幹細胞移植・臍帶血銀行・藥劑開發市場 是由出版商Kalorama Information在2012年01月所出版的。 這份英文市場調查報告書包含160 Pages 價格從美金3995起跳。

簡介

本報告書內容包括:幹細胞移植・臍帶血銀行・藥劑開發市場的現況與展望的調查分析、幹細胞的種類與概要、幹細胞的採取與用途、現在幹細胞治療所進行的疾病區分與開發中的疾病區分、幹細胞治療・臍帶血銀行的收益實績・預測（∼2020年：各發展情境）、幹細胞基礎的藥劑開發之技術費用的實績・預測（∼2020年：各種發展情境）、倫理的問題等各種課題等彙整、內容綱要摘記如下:

第1章 實施摘要

第2章 介紹

  • 醫療的幹細胞確實性
  • 幹細胞的種類
  • 幹細胞的採取
  • 胚性幹細胞
  • 治療目的的克隆複製
  • 未受精卵
  • 成體幹細胞
  • 白血球洗血療法
  • 末梢血
  • 臍帶血幹細胞
  • 移植過程
  • 癌性幹細胞
  • 其他有害的幹細胞
  • 藥劑開發的幹細胞
  • 幹細胞治療
  • 幹細胞為標的的醫藥品
  • 幹細胞的組織製作

第3章 現在的幹細胞治療

  • 癌
  • 白血病
  • 基因治療
  • 多發性骨髄瘤
  • 非何杰金氏淋巴瘤
  • 非癌性疾病
  • 再生不良性貧血
  • 免疫不全
  • 狼瘡
  • 鐮刀型紅血球病變
  • 其他症狀

第4章 幹細胞治療的開發

  • 阿茲海默症
  • 關節炎
  • 膀胱疾病
  • 火傷
  • 癌
  • 心血管疾病
  • 重症虚血肢
  • 糖尿病
  • 食道疾病
  • 失禁
  • 不孕症
  • 消化管疾病
  • 肝功能不全
  • 肺疾病
  • 多發性硬化症
  • 整形外科
  • 骨質疏鬆症
  • 帕金森氏症
  • 鐮刀型紅血球病變
  • 牙齒疾病
  • 皺紋/皮膚老化

第5章 幹細胞市場的預測

  • 最佳個案
  • 最容易引起的個案
  • 最壞的個案

第6章 幹細胞研究的課題

  • 倫理的問題
  • 美國：州及國家的獎勵
  • 幹細胞的專利
  • 其他醫療相關法律規範

附錄

圖表

目錄

Abstract

There is great interest in stem cells because they have potential to replace defective or damaged cells resulting from a variety of disorders and injuries, leading to a range of new regenerative therapies. Stem cells also have value as a research tool, as their in vitro study would allow scientists to learn more about the function of various organs and the development of particular diseases; stem cells may also eventually permit drug developers to test emerging therapies on diseased cells.

For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the pharmaceutical market. New scientific developments and recent changes in the U.S. Federal government's policy towards stem cells have made this potential more relevant. Kalorama Information has tackled the question in Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development. Kalorama analyst Alison Sahoo has built models to determine the best, moderate and worst case scenarios for the three key markets for stem cells:

  • Stem Cells in Drug Development
  • Stem Cells in Cord Blood Banking
  • Stem Cell Therapeutics

Stem cell therapeutics potentials are provided, broken down by disease:

  • Cardiovascular disease
  • Lung disease
  • Tooth disease
  • Arthritis
  • Wrinkles/aging skin
  • Incontinence
  • Osteoporosis
  • Diabetes
  • Cancer
  • Bladder disease
  • Infertility
  • Orthopedics
  • Alzheimer's disease
  • Burns (severe)
  • Lupus
  • Parkinson's disease
  • Liver failure
  • Multiple sclerosis
  • Critical limb ischemia
  • Intestinal disease
  • Sickle cell disease
  • Multiple myeloma
  • NH Lymphoma
  • Leukemia

The following trends are discussed in this report:

  • Ethical Questions
  • U.S. - State and Federal Initiatives
  • Research Funding
  • Cord Blood Initiatives
  • International Initiatives
  • Stem Cell Patents
  • Other Healthcare Regulations

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Scope and Methodolgy
  • Introduction
  • Current Stem Cell Therapies
  • Developmental Stem Cell Therapies
  • Issues In Stem Cell Research
  • Stem Cell Forecasts

CHAPTER TWO: INTRODUCTION

  • The Promise of Stem Cells In Medical Treatment
  • Types of Stem Cells
    • Embryonic Stem Cells
    • Adult Stem Cells
    • Cord Blood Stem Cells
  • Stem Cell Harvesting
  • Embryonic Stem Cells
  • Therapeutic Cloning
  • Unfertilized Eggs
  • Adult Stem Cells
  • Leukapheresis
  • Peripheral Blood
  • Cord Blood Stem Cells
  • Transplantation Approaches
    • Autologous Transplantation
    • Allogenic Transplantation
    • Transplantation Procedures
  • Cancerous Stem Cells
  • Other Harmful Stem Cells
  • Stem Cells in Drug Development
  • Stem Cell Therapeutics
  • Stem Cells Targeting Drugs
  • Stem Cell Generated Organs

CHAPTER THREE: CURRENT STEM CELL THERAPIES

  • Cancer
  • Leukemia
  • Gene Therapy
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
  • Non Cancerous Diseases
  • Aplastic anemia
  • Immunodeficiency
  • Lupus
  • Sickle Cell Disease
  • Other Conditions

CHAPTER FOUR: DEVELOPMENTAL STEM CELL THERAPIES

  • Alzheimer's Disease
  • Arthritis
  • Bladder Disease
  • Burns
  • Cancer
  • Cardiovascular Conditions
  • Critical Limb Ischemia
  • Diabestes
  • Esophagal Disease
  • Incontinence
  • Infertility
  • Intestinal Disease
  • Liver Failure
  • Lung Disease
  • Multiple Sclerosis
  • Orthopedics
  • Osteoporosis
  • Parkinson's Disease
  • Sickle Cell Disease
  • Tooth Disease
  • Wrinkles/Aging Skin

CHAPTER FIVE: STEM CELL FORECASTS

  • Best Case
    • Stem Cell Therapeutics
    • Umbilical Cord Blood Banking
    • Fees Related to Drug Development
  • Most Likely Case
    • Stem Cell Therapeutics
    • Umbilical Cord Blood Banking
    • Fees Related to Drug Development
  • Worst Case
    • Stem Cell Therapeutics
    • Umbilical Cord Blood Banking
    • Fees Related to Drug Development

CHAPTER SIX: ISSUES IN STEM CELL RESEARCH

  • Ethical Questions
  • U.S. - State and Federal Initiatives
    • Research Funding
    • Federal Funding
    • State Funding
    • Cord Blood Initiatives
    • International Initiatives
  • Stem Cell Patents
  • Other Healthcare Regulations

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-1 Total Market for Stem Cell Technologies in $ Millions, 2010 - 2020
  • Table 1-2 Stem Cell Therapeutics Market in $ Millions, 2010 - 2020
  • Table 1-3 Total Market for Cord Blood Banking Fees in $ Millions, 2010 - 2020
  • Table 1-4 Total Market for Stem Cell Drug Development Technologies in $ Millions, 2010 - 2020
  • Figure 1-1 Total Market for Stem Cells - Most Likely Case in $ Millions, 2010 - 2020

CHAPTER TWO: INTRODUCTION

  • Table 2-1 Established and Emerging Artificial Organ Products by Market Segment, 2010

CHAPTER THREE: CURRENT STEM CELL THERAPIES

  • Table 3-1 Types of Leukemia, 2011

CHAPTER FOUR: DEVELOPMENTAL STEM CELL THERAPIES

  • Table 4-1 Global Disease Populations Addressed by Potential Stem Cell Therapies, 2011
  • Table 4-2 Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2010 and 2020
  • Table 4-3 Estimated and Projected World Cancer Mortality by Selected Types of Cancer, 2010 and 2020
  • Table 4-4 Features and Types of Urinary Incontinence, 2011
  • Table 4-5 Types and Causes of Male Infertility, 2011
  • Table 4-6 Common Diseases of the Lungs, 2011

CHAPTER FIVE: STEM CELL FORECASTS

  • Table 5-1 Persons Affected by Key Stem Cell Therapeutic Targets in Millions, 2011
  • Table 5-2 Best Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 - 2020
  • Table 5-3 Best Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2010 - 2020
  • Table 5-4 131 Best Case: Cord Blood Banking Revenues in $ Millions, 2007 - 2020
  • Table 5-5 Best Case: Stem Cell-Based Drug Development Technology Fees, 2010 - 2020
  • Table 5-6 Best Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2010 - 2020
  • Table 5-7 Most Likely Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 - 2020
  • Table 5-8 Most Likely Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2010 - 2020
  • Table 5-9 Most Likely Case: Cord Blood Banking Revenues in $ Millions, 2010 - 2020
  • Table 5-10 Most Likely Case: Stem Cell-Based Drug Development Technology Fees in Millions, 2010 - 2020
  • Table 5-11 Most Likely Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2010 - 2020
  • Table 5-12 Worst Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 - 2020
  • Table 5-13 Worst Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2010 - 2020
  • Table 5-14 Worst Case: Cord Blood Banking Revenues in $ Millions, 2010-2020
  • Table 5-15 Worst Case: Stem Cell-Based Drug Development Technology Fees in Millions, 2010-2020
  • Table 5-16 Worst Case: Stem Cell-Based Drug Development Technology Fees in $ Millions 2010-2020

CHAPTER SIX: ISSUES IN STEM CELL RESEARCH

  • Table 6-1 NIH Funding for Stem Cell Research, 2002 - 2010 in $ Million
  • Table 6-2 U.S. State Embryonic & Fetal Research Laws
  • Table 6-3 Positions on Human ES Cell Research by Country, 2011
  • Table 6-4 EU Laws on hESC Research by Country

Press Release

幹細胞技術市場將擴大的前景

2012年02月10日

Global Information Inc.開始代理銷售Kalorama Information所發行的報告書「Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development (幹細胞：全球的幹細胞移植・臍帶血銀行・藥劑開發市場)」。

醫療市場的調査公司Kalorama Information表示，幹細胞技術市場在2012年有7億美元以上的擴大之前景、如果有更多進一步的動機來支撐，也可能達到10億美元以上。

本報告書中，提示了在美國新取得許可的幹細胞使用狀況與其所伴隨的研究資金調達等豐富內容，更有數個快速變化的要因、變動幅度的市場預測。

「幹細胞市場是會嚴苛的情況或者樂觀的道路傾斜、取決於好幾個要因。

以可能性高的假設過程來說、建立者持續擴大利用倫理上得到許可的成人幹細胞、並且不受到專利與使用費的支付等財政性因素影響。

甚至，雖然只是少數，開發中最新技術的一部分，得到安全性的證實、通過審議後、顯示了現在治療的實質優點，我們如此預測著。」Kalorama Information的本報告書作者Bruce Carlson如此描述。

透過本報告書、細胞治療目前限於數種疾病的治療。例如白血病、多發性骨髄種瘤、以及非何杰金氏淋巴瘤等種瘤性疾病。

但是非癌性疾病的再生不良性貧血、免疫不全症、狼瘡等的治療中、幹細胞的使用也在增加。

Kalorama Information預測臍帶血銀行將帶來收益的成長。

臍帶血幹細胞是很快可以利用的供給之一、不需要新技術。甚至包含幹細胞中爭論最少的項目、支持著多數人出生時要採取臍帶血。
Back to Top